GlassScriptPhysician profile
Jonathan P Barcalow
NPI 1851908362
$2,418.69
in general payments reported to CMS, 2019-2025
28 companies · $850 in 2025
The $850 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $282 · 2022: $142 · 2023: $195 · 2024: $950 · 2025: $850.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,995.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,994.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $478.83 | 2021-2025 | Repatha, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $461.21 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $351.47 | 2021-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $219.46 | 2024-2025 | |
| Pfizer INC. | $143.72 | 2023-2025 | |
| Axsome Therapeutics, INC. | $94.55 | 2025 | Sunosi, Auvelity |
| Merck Sharp & Dohme LLC | $63.92 | 2022-2024 | Gardasil 9, Capvaxive, Gardasil |
| Novartis Pharmaceuticals Corporation | $62.96 | 2024-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $55.63 | 2025 | Caplyta |
| Phathom Pharmaceuticals, INC. | $54.74 | 2024-2025 | Voquezna |
| Viatris Specialty LLC | $42.31 | 2025 | Yupelri |
| Exact Sciences Corporation | $41.76 | 2024 | Cologuard Collection Kit |
| Azurity Pharmaceuticals, INC. | $39.08 | 2025 | Alvesco |
| Mylan Specialty L.P. | $35.81 | 2024 | Yupelri |
| Lilly USA, LLC | $33.34 | 2025 | Mounjaro |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $33.34 | 2022-2025 | Trelegy Ellipta, Arexvy |
| Stryker Corporation | $26.83 | 2025 | Clottriever Bold Catheter |
| Dexcom, INC. | $18.94 | 2024 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $17.95 | 2024 | Rexulti |
| Sumitomo Pharma America, INC. | $17.11 | 2024 | Gemtesa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.10 | 2025 | Jardiance |
| Acella Pharmaceuticals, LLC | $16.52 | 2025 | NP Thyroid 60 |
| Teva Pharmaceuticals USA, INC. | $15.96 | 2025 | Ajovy |
| Harmony Biosciences LLC | $15.48 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.40 | 2025 | Xifaxan |
| Shield Therapeutics INC | $15.23 | 2023 | Accrufer |
| Almatica Pharma LLC | $15.04 | 2025 | Loreev Xr |
| Xeris Pharmaceuticals, INC. | $15.00 | 2024 | Gvoke Hypopen |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Barcalow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.